Journal of the American Academy of Dermatology · 2007
From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Snoo Femke A, Kroon Marije W, Bergman Wilma, ter Huurne Jeanet A C, Houwing-Duistermaat Jeanine J, van Mourik Leny, Snels Dyon G C T M, Breuning Martijn H, Willemze Rein, Frants Rune R, Gruis Nelleke A
Аннотация
BACKGROUND: Atypical nevi (AN), present in either a familial or a sporadic setting, are strong indicators of increased melanoma risk.
OBJECTIVE: To estimate the extent of this risk and the extent of reclassification of sporadic to familial cases during follow-up.
METHODS: We studied 167 sporadic patients with AN (>or=5). At the end of follow-up we updated the family history regarding melanoma and performed germline mutation analysis of the known melanoma susceptibility genes.
RESULTS: We found a relative risk for melanoma of 46.1 (95% confidence interval 21.0-87.5). Six of 167 patients were carriers of a CDKN2A mutation. At the end of follow-up, 10 of 136 patients with sporadic AN reported being a member of a melanoma family.
LIMITATIONS: This study was conducted in an area with a founder mutation in many of its melanoma families; therefore the results may not be applicable to other populations.
CONCLUSION: We report a high relative risk of 46.1 of melanoma development in patients with sporadic AN. A significant proportion of this Dutch cohort reported additional cases in their families over time.
OBJECTIVE: To estimate the extent of this risk and the extent of reclassification of sporadic to familial cases during follow-up.
METHODS: We studied 167 sporadic patients with AN (>or=5). At the end of follow-up we updated the family history regarding melanoma and performed germline mutation analysis of the known melanoma susceptibility genes.
RESULTS: We found a relative risk for melanoma of 46.1 (95% confidence interval 21.0-87.5). Six of 167 patients were carriers of a CDKN2A mutation. At the end of follow-up, 10 of 136 patients with sporadic AN reported being a member of a melanoma family.
LIMITATIONS: This study was conducted in an area with a founder mutation in many of its melanoma families; therefore the results may not be applicable to other populations.
CONCLUSION: We report a high relative risk of 46.1 of melanoma development in patients with sporadic AN. A significant proportion of this Dutch cohort reported additional cases in their families over time.